Peptide Cerebrolysin

Peptide Cerebrolysin

Cerebrolysin improves the brain’s aerobic metabolic processes, and possesses neuroprotective mechanisms which may slow or prevent brain cellular impairment or death, as a result of stroke or Traumatic Brain Injury (TBI). Cerebrolysin penetrates the blood-brain barrier after it is administered, which means that it can reach and effect the brain’s neurons directly. It has been used for treating stroke, traumatic brain injury, dementia, and Alzheimer’s and other neurologic disease. has been shown to have actions similar to our natural internal nerve growth factors, which maintain peripheral and central nervous system cellular efficiency.


Studied Benefits of Cerebrolysin:

  • Lowers inflammation in the brain
  • Promotes the growth of new brain cells
  • Increases energy production in brain cells
  • Improves brain cell to cell communication
  • Protects and may prevent the death of brain cells affected by stroke or Traumatic Brain injury (TBI).
  • Decreases the level of beta-amyloid deposits in the brain, which are linked to Alzheimer’s disease.
  • A review of 15 studies including over 2,400 subjects showed that Cerebrolysin slowed disease progression in patients with dementia and Alzheimer’s disease.
  • ADHD symptoms were improved by approximately 75% in a research study of 60 children with the diagnosis.
  • A combination of Cerebrolysin with antidepressants helped patients more than antidepressants alone in patients not adequately treated by their antidepressant medication.

This is safe and generally well-tolerated by patients with only minor temporary side effects being reported- headache, nausea.


Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent (M. Panisset, S. Gauthier, H. Moessler, M. Windisch)

Conclusions: Treatment was well tolerated and resulted in significant improvements in the global score two months after the end of active treatment.

Research Conclusion:

In preclinical studies, cerebrolysin protected neurons and brain tissues from damage, reduced inflammation, promoted the formation of new neural connections, lessened cognitive impairment and reduced the plaques and tangles common in Alzheimer’s patients. There are also published clinical trials showing that this improved cognitive function in older people with memory problems, and also in those with schizophrenia.